´ëÇÑÀü¸³¼±ÇÐȸ 2021 KPS-APSU Joint International Symposium (1ÀÏÂ÷) : 2021-09-03±³À°ÀÏÀÚ : 2021-09-03
±³À°Àå¼Ò : ±×·£µåÀÎÅÍÄÜƼ³ÙÅ» ¼¿ï Æĸ£³ª½º (5Ãþ ·ÎÁî·ë)
±³À°ÁÖÁ¦ :
2021 KPS-APSU Joint International Symposium (1ÀÏÂ÷)ÁÖÃÖ±â°ü : ´ëÇÑÀü¸³¼±ÇÐȸ
´ã´çÀÚ : ¹èÁø¼º
¿¬¶ôó : 02-2038-7988
À̸ÞÀÏ :
gaonpco@gaonpco.com ±³À°Á¾·ù : ºñ´¢ÀÇÇаú
Âü¼®¿¹»óÀοø : 100¸í
Èñ¸ÁÆòÁ¡ : 2Á¡
Áö¿ª :
¼¿ïƯº°½Ã±³À°½Ã°£ : 3 ½Ã°£ 20ºÐ
¼¼ºÎ¼ö°·á : 30,000¿ø
ºñ°í »çÀüµî·Ï: ±¹³» (30,000¿ø), ±¹¿Ü (¹«·á) ÇöÀåµî·Ï ºÒ°¡
±¸ºÐ ¿ùÀÏ °ÀÇ½Ç ½Ã°£ ±³À°Á¦¸ñ °»ç¸í(¼Ò¼Ó) Çʼö°ú¸ñ
±³À°½Ã°£ 09-03 ±×·£µåÀÎÅÍÄÜƼ³ÙÅ» ¼¿ï Æĸ£³ª½º (5Ãþ ·ÎÁî·ë) 13:20~13:30 Triggers for Delayed Intervention for Small Renal Masses Undergoing Active Surveillance Źü½Ä(°í·ÁÀÇ´ë)
±³À°½Ã°£ 09-03 ±×·£µåÀÎÅÍÄÜƼ³ÙÅ» ¼¿ï Æĸ£³ª½º (5Ãþ ·ÎÁî·ë) 13:30~13:40 Partial Nephrectomy Versus Radiofrequency Ablation for Small Renal Masses: Pros & Cons ÇÏÀ±¼ö(°¡Å縯ÀÇ´ë)
±³À°½Ã°£ 09-03 ±×·£µåÀÎÅÍÄÜƼ³ÙÅ» ¼¿ï Æĸ£³ª½º (5Ãþ ·ÎÁî·ë) 13:40~14:00 The Role of Cytoreductive Nephrectomy for Metastatic Renal Cell Carcinoma in 2021 Chris G. WOOD(MD Anderson CC USA)
Åä·Ð 09-03 ±×·£µåÀÎÅÍÄÜƼ³ÙÅ» ¼¿ï Æĸ£³ª½º (5Ãþ ·ÎÁî·ë) 14:00~14:25 Panel Discussion Norio NONOMURA(Osaka University Graduate School of Medicine Japan)
ÈÞ½Ä 09-03 ±×·£µåÀÎÅÍÄÜƼ³ÙÅ» ¼¿ï Æĸ£³ª½º (5Ãþ ·ÎÁî·ë) 14:25~14:35 Coffee Break ()
±³À°½Ã°£ 09-03 ±×·£µåÀÎÅÍÄÜƼ³ÙÅ» ¼¿ï Æĸ£³ª½º (5Ãþ ·ÎÁî·ë) 14:35~14:45 What is the Optimal Therapy for BCG Unresponsive High-Risk NMIBC: Intravesical Chemotherapy or Systemic Therapy? À°Çüµ¿(¼¿ïÀÇ´ë)
±³À°½Ã°£ 09-03 ±×·£µåÀÎÅÍÄÜƼ³ÙÅ» ¼¿ï Æĸ£³ª½º (5Ãþ ·ÎÁî·ë) 14:45~14:55 Optimal Strategy of Trimodality Therapy: Who, How, and When? ¼Û¿Ï(¼º±Õ°üÀÇ´ë)
±³À°½Ã°£ 09-03 ±×·£µåÀÎÅÍÄÜƼ³ÙÅ» ¼¿ï Æĸ£³ª½º (5Ãþ ·ÎÁî·ë) 14:55~15:15 Neoadjuvant vs Adjuvant Chemotherapy/Immunotherapy in High-Risk UTUC: Indications and Controversies Seth LERNER(Baylor College of Medicine USA)
Åä·Ð 09-03 ±×·£µåÀÎÅÍÄÜƼ³ÙÅ» ¼¿ï Æĸ£³ª½º (5Ãþ ·ÎÁî·ë) 15:15~15:40 Panel Discussion ¼Û»óÈÆ(¿ï»êÀÇ´ë)
ÈÞ½Ä 09-03 ±×·£µåÀÎÅÍÄÜƼ³ÙÅ» ¼¿ï Æĸ£³ª½º (5Ãþ ·ÎÁî·ë) 15:40~15:50 Coffee Break ()
±³À°½Ã°£ 09-03 ±×·£µåÀÎÅÍÄÜƼ³ÙÅ» ¼¿ï Æĸ£³ª½º (5Ãþ ·ÎÁî·ë) 15:50~16:00 How Should We Interpret and Manage PI-RADS 3 Lesions on mpMRI? ³ªÁØä(¿¬¼¼ÀÇ´ë)
±³À°½Ã°£ 09-03 ±×·£µåÀÎÅÍÄÜƼ³ÙÅ» ¼¿ï Æĸ£³ª½º (5Ãþ ·ÎÁî·ë) 16:00~16:20 Focal Therapy: Is It a Standard of Care? Robert E. REITER(UCLAUSA)
±³À°½Ã°£ 09-03 ±×·£µåÀÎÅÍÄÜƼ³ÙÅ» ¼¿ï Æĸ£³ª½º (5Ãþ ·ÎÁî·ë) 16:20~16:30 Updates on Immunotherapy Combined with Chemotherapy for Advanced, Metastatic Disease À¯»óÁØ(¼¿ïÀÇ´ë)
Åä·Ð 09-03 ±×·£µåÀÎÅÍÄÜƼ³ÙÅ» ¼¿ï Æĸ£³ª½º (5Ãþ ·ÎÁî·ë) 16:30~17:00 Panel Discussion ÀüȲ±Õ(¼º±Õ°üÀÇ´ë)